Navigation Links
Syndax Pharmaceuticals to Present at Sachs Biotech in Europe Investor Forum
Date:9/22/2010

WALTHAM, Mass., Sept. 22 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced that Joanna Horobin, M.D., the company's president and CEO, will present at the Sachs Biotech in Europe Investor Forum Wednesday, September 29, 2010 at the Radisson Blu hotel in Zurich, Switzerland.

Dr. Horobin will be a panelist on the Oncology Investment Panel at 12:00 pm CEST.  Her presentation will be given at 5:00 p.m. CEST and will include an overview of upcoming milestones including the ongoing phase 2 clinical program for entinostat in breast, lung, colorectal cancer and hematologic malignancies.

The presentation will be available at Syndax's website, www.syndax.com.

About SyndaxSyndax Pharmaceuticals, Inc. is a Waltham, MA-based, oncology-focused pharmaceutical company. Syndax is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens. Formed in 2005, the company's intellectual property is based on work from scientific founder Ronald Evans, Ph.D., recipient of the 2004 Albert Lasker Prize for Basic Medical Research, a Member of the National Academy of Sciences, a professor at the Salk Institute for Biological Studies and a Howard Hughes Medical Institute Investigator.

Syndax holds rights to entinostat from Bayer Schering Pharma and is backed by top-tier Venture Capital firms: Domain Associates, MPM Capital, Avalon, Pappas and Forward Ventures.  For more information please visit www.syndax.com.Contact InformationJoanna Horobin, M.D.

Danielle Bertrand Syndax Pharmaceuticals, Inc.

WCG Tel: 781-419-1402

Tel: 415-946-1056 jhorobin@syndax.com

dbertrand@wcgworld.com
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
2. Reportlinker Adds E7: The Outlook for Pharmaceuticals to 2012
3. Access Pharmaceuticals, Inc. Signs $30M MuGard Supply Agreement With RHEI Pharmaceuticals HK LTD.
4. Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing
5. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Penwest Pharmaceuticals
6. NewBridge Pharmaceuticals Completes $12 Million First Close of Series B Financing, Announces Senior Executive Appointments
7. Lead Plaintiffs Attorney In Forest Pharmaceuticals Case Says $313 Million Award Is Tip of the Iceberg of Future Off-Label Marketing Lawsuits
8. Cempra Pharmaceuticals to Present at the UBS Global Life Sciences Conference
9. HRA Pharma and Watson Pharmaceuticals Expand Marketing Partnership for Novel Emergency Contraceptive to Canada
10. Onyx Pharmaceuticals to Present at the UBS Global Life Sciences Conference
11. LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... July 20, 2017  Prime Therapeutics LLC (Prime) released this ... M.D., following today,s Institute for Clinical and Economic Review,s (ICER) ... the effectiveness and value of abuse-deterrent formulations (ADF) of opioids. ... roundtable at the meeting. ... cost benefit to the use of abuse-deterrent formulations (ADF) in ...
(Date:7/14/2017)... 2017 It should come as no surprise to ... in the midst of a crippling opioid epidemic. According to ... number of overdose deaths from opiate-based medications has quadrupled, Says, ... million dead from 2001 to 2015". During this time, the ... similarly quadrupled, drawing a compelling link between prescription and eventual ...
(Date:7/12/2017)... INDIANAPOLIS , July 12, 2017  Eli Lilly and ... settlement agreement with generic companies to resolve pending patent litigation ... Virginia regarding the Cialis ® ... expire on April 26, 2020. As part of the agreement, ... on September 27, 2018. "The unit dose patent ...
Breaking Medicine Technology:
(Date:7/24/2017)... OH (PRWEB) , ... July 24, 2017 , ... ... place August 13-17 in National Harbor, MD. This year's theme focuses on the ... the principal benchmarks for quality and integrity in testing and calibration will be ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... A Southern ... food addiction to sexual abuse, and how she has overcome them. “Forbidden Memories: A ... in her life and how she has risen above. , In “Memories,” readers get ...
(Date:7/24/2017)... Church, VA (PRWEB) , ... July 24, 2017 ... ... and Managers, **Presented by FDAnews and MSceppa Consulting **, Aug. 22-23, 2017 – ... ends on Friday, July 28. , Increased FDA scrutiny and growing demands to ...
(Date:7/24/2017)... ... ... customizable and interactive Bible study guide for children. “The Perfect Gift” is the creation of ... accepted Christ as her Savior, yet never studied His word, surrendered to His will, or ... book to her children, so they would know the importance of the truth. She ...
(Date:7/24/2017)... ... 24, 2017 , ... The Center for Addiction Recovery Training ... host a second Multiple Pathways of Recovery Conference on October 23-26, 2017. This ... from CCAR’s foundational principle – a belief in multiple pathways of recovery, aims ...
Breaking Medicine News(10 mins):